Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
36.35
Dollar change
+1.78
Percentage change
5.15
%
IndexRUT P/E- EPS (ttm)-4.64 Insider Own24.84% Shs Outstand34.21M Perf Week7.99%
Market Cap1.36B Forward P/E- EPS next Y-2.02 Insider Trans-1.19% Shs Float28.19M Perf Month-4.01%
Income-135.89M PEG- EPS next Q-1.23 Inst Own75.11% Short Float25.52% Perf Quarter77.58%
Sales17.45M P/S78.12 EPS this Y7.16% Inst Trans1.81% Short Ratio9.30 Perf Half Y130.21%
Book/sh5.76 P/B6.31 EPS next Y52.89% ROA-55.01% Short Interest7.20M Perf Year196.98%
Cash/sh6.07 P/C5.99 EPS next 5Y- ROE-69.71% 52W Range11.33 - 40.40 Perf YTD79.51%
Dividend Est.- P/FCF- EPS past 5Y-132.82% ROI-59.52% 52W High-10.02% Beta1.05
Dividend TTM- Quick Ratio6.85 Sales past 5Y-17.43% Gross Margin85.48% 52W Low220.83% ATR (14)2.10
Dividend Ex-Date- Current Ratio6.93 EPS Y/Y TTM-80.72% Oper. Margin-820.53% RSI (14)63.15 Volatility5.32% 6.57%
Employees244 Debt/Eq0.16 Sales Y/Y TTM-32.42% Profit Margin-778.89% Recom1.33 Target Price52.33
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q-157.80% Payout- Rel Volume1.34 Prev Close34.57
Sales Surprise138.99% EPS Surprise4.53% Sales Q/Q30.76% EarningsFeb 27 BMO Avg Volume773.50K Price36.35
SMA208.16% SMA5017.32% SMA20073.98% Trades Volume1,033,264 Change5.15%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Neutral $19
Jul-18-23Initiated William Blair Outperform $44
May-18-23Initiated Guggenheim Buy
Aug-01-22Initiated Barclays Overweight $40
Dec-21-21Initiated H.C. Wainwright Buy $40
Nov-23-21Initiated Oppenheimer Outperform $55
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Mar-06-24 09:55AM
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
12:00PM Loading…
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
06:34AM
06:00AM
Feb-22-24 08:00AM
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
03:32PM Loading…
Dec-21-23 03:32PM
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
Aug-03-23 02:14PM
Aug-01-23 10:30PM
Jul-31-23 04:29PM
Jul-25-23 07:00AM
02:04PM Loading…
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Jun-05-23 08:30AM
May-09-23 04:05PM
May-08-23 08:30AM
May-05-23 08:22AM
May-03-23 04:30PM
Apr-24-23 08:30AM
Apr-18-23 06:04AM
Apr-06-23 03:52PM
Mar-17-23 06:28AM
Mar-13-23 04:05PM
Mar-09-23 10:00AM
Mar-02-23 04:30PM
Feb-24-23 11:44AM
Jan-24-23 04:33AM
Dec-16-22 07:00AM
Dec-15-22 12:45PM
08:30AM
Dec-08-22 06:55AM
Nov-11-22 06:03AM
Nov-09-22 08:45AM
07:00AM
Oct-25-22 08:30AM
Oct-17-22 09:26AM
Oct-11-22 08:30AM
Oct-06-22 08:30AM
Sep-29-22 08:30AM
Sep-27-22 12:00PM
Sep-17-22 10:23AM
Sep-07-22 07:00AM
Aug-11-22 05:25PM
04:05PM
Aug-05-22 08:30AM
Jul-25-22 08:00AM
Jun-29-22 06:51AM
May-27-22 09:00AM
May-14-22 08:19AM
May-11-22 06:30AM
May-10-22 06:55PM
04:05PM
May-09-22 01:49PM
May-06-22 09:00AM
May-05-22 08:30AM
May-03-22 03:00PM
06:58AM
May-02-22 07:01AM
07:00AM
Apr-29-22 09:23PM
Apr-26-22 08:30AM
Apr-21-22 03:05AM
Mar-14-22 04:05PM
Mar-09-22 05:00PM
Feb-03-22 09:00AM
Feb-02-22 04:30PM
07:00AM
Jan-04-22 09:00AM
Nov-23-21 04:30PM
Nov-10-21 04:30PM
Nov-09-21 04:05PM
Nov-05-21 12:04PM
Nov-04-21 11:28AM
09:45AM
Nov-02-21 05:00PM
Oct-19-21 02:38PM
Oct-11-21 07:43PM
Aug-13-21 07:07AM
Aug-12-21 09:00AM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Azamian Bobak R.President/CEO and Board ChairMar 18 '24Sale30.6010,415318,69926,456Mar 19 07:05 PM
Neervannan SeshadriChief Operating OfficerMar 18 '24Sale30.604,879149,29764,767Mar 19 07:03 PM
Mottiwala AzizChief Commercial OfficerMar 18 '24Sale30.604,766145,84054,075Mar 19 07:08 PM
Wahl BryanGeneral CounselMar 18 '24Sale30.604,436135,74240,951Mar 19 07:05 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 18 '24Sale30.604,314132,00834,181Mar 19 07:04 PM
Azamian Bobak R.President/CEO and Board ChairDec 27 '23Sale20.228,000161,760830,106Dec 29 05:08 PM
Azamian Bobak R.President/CEO and Board ChairDec 20 '23Sale20.2740,000810,623838,106Dec 22 05:30 PM
Trevejo Jose M.CHIEF MEDICAL OFFICERDec 20 '23Sale20.002,25245,0402,251Dec 22 05:32 PM
Goldberg Andrew D.DirectorDec 15 '23Buy18.961,00018,9603,000Dec 19 06:30 PM
Wahl BryanGeneral CounselNov 30 '23Sale16.318,356136,28631,966Dec 01 04:55 PM
Whitfield Dianne C.Chief Human Resources OfficerNov 30 '23Sale16.318,355136,27026,784Dec 01 04:58 PM
Whitfield Dianne C.Chief Human Resources OfficerNov 29 '23Option Exercise0.0023,920035,139Dec 01 04:58 PM
Wahl BryanGeneral CounselNov 29 '23Option Exercise0.0023,920040,322Dec 01 04:55 PM
Azamian Bobak R.President/CEO and Board ChairNov 15 '23Sale18.378,000146,933878,106Nov 17 04:50 PM
Azamian Bobak R.President/CEO and Board ChairOct 18 '23Sale13.248,000105,920886,106Oct 20 04:41 PM
Trevejo Jose M.CHIEF MEDICAL OFFICEROct 05 '23Sale18.001,60428,8724,503Oct 06 05:21 PM
Azamian Bobak R.President/CEO and Board ChairSep 20 '23Sale17.218,000137,680894,106Sep 22 05:30 PM
Azamian Bobak R.President/CEO and Board ChairAug 23 '23Sale17.238,000137,840902,106Aug 25 05:12 PM
Lin Elizabeth YeuDirectorAug 15 '23Buy16.809,506159,70115,866Aug 17 06:02 PM
Azamian Bobak R.President/CEO and Board ChairJul 19 '23Sale20.01103,9002,078,984910,106Jul 21 05:42 PM
Mottiwala AzizChief Commercial OfficerJul 19 '23Sale20.052,40048,12045,806Jul 21 05:46 PM
Azamian Bobak R.President/CEO and Board ChairJul 12 '23Sale17.359,000156,1501,014,006Jul 14 04:40 PM
Azamian Bobak R.President/CEO and Board ChairJun 21 '23Sale18.638,000149,0401,023,006Jun 23 04:29 PM
Azamian Bobak R.President/CEO and Board ChairJun 14 '23Sale18.589,000167,2201,031,006Jun 16 04:48 PM
Azamian Bobak R.President/CEO and Board ChairJun 08 '23Sale20.013,10062,0311,040,006Jun 12 05:40 PM
Mottiwala AzizChief Commercial OfficerJun 08 '23Sale20.001002,00048,086Jun 12 05:25 PM
Mottiwala AzizChief Commercial OfficerJun 07 '23Sale19.342,50048,35048,186Jun 08 07:16 PM
Mottiwala AzizChief Commercial OfficerJun 06 '23Sale18.612,14339,88150,686Jun 08 07:16 PM
Azamian Bobak R.President/CEO and Board ChairMay 17 '23Sale15.908,000127,2001,043,106May 19 07:08 PM
Azamian Bobak R.President/CEO and Board ChairMay 10 '23Sale16.809,000151,2001,051,106May 12 05:08 PM
Azamian Bobak R.President/CEO and Board ChairMay 01 '23Sale15.105,84188,1991,060,106May 02 07:06 PM
Azamian Bobak R.President/CEO and Board ChairApr 28 '23Sale15.134,27864,7261,065,947May 02 07:06 PM
Azamian Bobak R.President/CEO and Board ChairApr 21 '23Sale15.032,31134,7341,070,225Apr 25 05:22 PM
Greenstein Leonard M.Chief Financial OfficerApr 20 '23Sale14.025,00070,10026,785Apr 21 05:53 PM
Azamian Bobak R.President/CEO and Board ChairApr 19 '23Sale13.608,000108,8001,072,536Apr 21 05:49 PM
Last Close
Mar 28 04:00PM ET
1.35
Dollar change
+0.04
Percentage change
3.05
%
PASG Passage Bio Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.86 Insider Own33.54% Shs Outstand54.94M Perf Week-1.46%
Market Cap75.06M Forward P/E- EPS next Y-0.98 Insider Trans-0.19% Shs Float36.95M Perf Month-21.97%
Income-102.06M PEG- EPS next Q-0.36 Inst Own20.93% Short Float3.28% Perf Quarter43.25%
Sales0.00M P/S- EPS this Y35.97% Inst Trans-6.59% Short Ratio2.82 Perf Half Y103.19%
Book/sh2.03 P/B0.67 EPS next Y18.10% ROA-51.80% Short Interest1.21M Perf Year39.18%
Cash/sh2.06 P/C0.66 EPS next 5Y- ROE-65.29% 52W Range0.58 - 1.79 Perf YTD33.66%
Dividend Est.- P/FCF- EPS past 5Y-46.23% ROI-76.05% 52W High-24.58% Beta1.29
Dividend TTM- Quick Ratio7.22 Sales past 5Y0.00% Gross Margin- 52W Low134.74% ATR (14)0.17
Dividend Ex-Date- Current Ratio7.22 EPS Y/Y TTM25.46% Oper. Margin0.00% RSI (14)49.06 Volatility9.82% 12.70%
Employees58 Debt/Eq0.24 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q38.47% Payout- Rel Volume0.43 Prev Close1.31
Sales Surprise- EPS Surprise22.28% Sales Q/Q- EarningsMar 04 BMO Avg Volume429.80K Price1.35
SMA20-8.13% SMA508.77% SMA20050.17% Trades Volume185,410 Change3.05%
Date Action Analyst Rating Change Price Target Change
Mar-08-22Downgrade JP Morgan Overweight → Neutral
Jan-19-22Downgrade Goldman Buy → Neutral $29 → $6
Jul-01-21Initiated Raymond James Outperform $29
Jun-15-21Initiated BTIG Research Buy $25
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Mar-07-24 12:00PM
Mar-06-24 01:52PM
Mar-05-24 07:00AM
Mar-04-24 07:00AM
Feb-27-24 07:00AM
07:09PM Loading…
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Dec-25-23 10:14PM
Dec-20-23 07:00AM
Nov-17-23 04:30PM
Nov-13-23 07:00AM
Oct-30-23 07:00AM
Oct-20-23 04:30PM
Sep-25-23 07:00AM
Aug-11-23 10:04AM
07:15AM Loading…
Aug-07-23 07:15AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-24-23 12:37PM
Jul-06-23 11:17AM
Jun-05-23 07:00AM
May-11-23 07:00AM
May-04-23 07:00AM
Apr-21-23 04:01PM
Apr-17-23 07:00AM
Mar-29-23 09:02AM
Mar-27-23 07:00AM
Mar-08-23 07:14AM
Mar-07-23 12:42AM
07:00AM Loading…
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-20-23 05:59PM
Feb-15-23 07:00AM
Jan-20-23 04:01PM
Jan-07-23 07:39AM
Dec-14-22 12:13PM
07:00AM
Nov-21-22 05:24AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:30AM
Oct-14-22 04:01PM
Oct-11-22 12:25PM
Oct-10-22 07:00AM
Sep-26-22 07:00AM
Aug-19-22 04:01PM
Aug-11-22 07:00AM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-28-22 07:30AM
Jul-21-22 04:01PM
Jul-12-22 08:19AM
Jul-06-22 07:00AM
Jun-09-22 07:30AM
Jun-08-22 07:30AM
Jun-01-22 10:19AM
07:30AM
May-20-22 04:01PM
May-18-22 07:00AM
May-16-22 07:00AM
May-09-22 07:00AM
May-04-22 10:55AM
May-03-22 02:13PM
May-02-22 04:01PM
Apr-22-22 04:01PM
Mar-29-22 07:00AM
Mar-28-22 07:00AM
Mar-15-22 11:22AM
11:12AM
07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Mar-01-22 07:00AM
Feb-24-22 07:00AM
Feb-11-22 11:00AM
Feb-01-22 12:49PM
Jan-31-22 07:00AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-17-21 07:00AM
Dec-08-21 02:35PM
07:00AM
Nov-30-21 11:08AM
Nov-19-21 04:00PM
Nov-12-21 05:51AM
Nov-09-21 07:00AM
Nov-04-21 07:00AM
Nov-01-21 03:05PM
Oct-28-21 07:00AM
Sep-29-21 04:42PM
Sep-27-21 07:00AM
Sep-17-21 04:01PM
Sep-07-21 07:00AM
Sep-02-21 07:00AM
Aug-05-21 07:00AM
Aug-04-21 09:00PM
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forman Mark SCHIEF MEDICAL OFFICERFeb 13 '24Sale0.971,6381,58948,631Feb 13 07:34 PM
Borthwick KathleenSVP, INTERIM CFOFeb 13 '24Sale0.971,4701,42628,466Feb 13 07:36 PM
Forman Mark SChief Medical OfficerJan 02 '24Sale0.9115,81314,39045,269Jan 03 04:21 PM
Cale Edgar B.GC & Corporate SecretaryJan 02 '24Sale0.9115,81314,39045,995Jan 03 04:19 PM
King SimonaChief Financial OfficerJul 28 '23Option Exercise0.0031,250035,447Aug 01 04:36 PM
King SimonaChief Financial OfficerJul 28 '23Sale0.8811,45310,07923,994Aug 01 04:36 PM
ORBIMED ADVISORS LLC10% OwnerJun 28 '23Buy0.84575,195483,1648,034,000Jun 29 04:42 PM
ORBIMED ADVISORS LLC10% OwnerJun 27 '23Buy0.84617,382518,6017,458,805Jun 29 04:42 PM
Fotopoulos AlexandrosChief Technical OfficerJun 16 '23Sale0.934,0523,77828,693Jun 20 04:10 PM
Fotopoulos AlexandrosChief Technical OfficerJun 15 '23Option Exercise0.0012,500032,745Jun 20 04:10 PM
King SimonaChief Financial OfficerApr 18 '23Option Exercise0.006,25006,250Apr 20 04:28 PM
King SimonaChief Financial OfficerApr 18 '23Sale1.052,0532,1562,053Apr 20 04:28 PM
Last Close
Mar 28 04:00PM ET
10.62
Dollar change
-0.43
Percentage change
-3.89
%
PHAT Phathom Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-3.89 Insider Own55.49% Shs Outstand57.97M Perf Week15.94%
Market Cap621.06M Forward P/E- EPS next Y-3.23 Insider Trans-10.32% Shs Float26.03M Perf Month-1.48%
Income-201.59M PEG- EPS next Q-1.20 Inst Own44.62% Short Float40.12% Perf Quarter14.69%
Sales0.68M P/S913.32 EPS this Y-17.58% Inst Trans6.89% Short Ratio12.52 Perf Half Y3.01%
Book/sh-1.26 P/B- EPS next Y30.00% ROA-69.68% Short Interest10.44M Perf Year55.04%
Cash/sh6.52 P/C1.63 EPS next 5Y- ROE-3489.00% 52W Range6.07 - 17.02 Perf YTD16.32%
Dividend Est.- P/FCF- EPS past 5Y-137.06% ROI-55.18% 52W High-37.60% Beta0.63
Dividend TTM- Quick Ratio10.22 Sales past 5Y0.00% Gross Margin-8.80% 52W Low75.10% ATR (14)0.90
Dividend Ex-Date- Current Ratio10.25 EPS Y/Y TTM22.99% Oper. Margin-24532.40% RSI (14)60.84 Volatility12.51% 9.41%
Employees452 Debt/Eq- Sales Y/Y TTM- Profit Margin-29558.80% Recom1.25 Target Price22.71
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-4.23% Payout- Rel Volume1.06 Prev Close11.05
Sales Surprise70.12% EPS Surprise-29.05% Sales Q/Q- EarningsMar 07 BMO Avg Volume834.53K Price10.62
SMA2012.86% SMA5025.40% SMA2001.38% Trades Volume886,406 Change-3.89%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Reiterated Needham Buy $23 → $26
Aug-09-23Initiated H.C. Wainwright Buy $28
May-11-23Upgrade Evercore ISI In-line → Outperform
Mar-13-23Initiated Craig Hallum Buy $21
Oct-21-22Initiated Jefferies Buy $16
May-06-22Downgrade Evercore ISI Outperform → In-line
May-12-21Upgrade Goldman Sell → Neutral $40 → $48
Feb-17-21Initiated BMO Capital Markets Outperform $63
Feb-02-21Initiated Guggenheim Buy $60
Jun-26-20Downgrade Goldman Neutral → Sell $34
Mar-26-24 08:00AM
Mar-08-24 03:05PM
01:57AM
Mar-07-24 01:51PM
01:38PM
08:00AM Loading…
08:00AM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Dec-14-23 08:00AM
Dec-06-23 08:00AM
Nov-28-23 08:00AM
Nov-09-23 09:34AM
08:00AM
Nov-01-23 05:00PM
08:00AM Loading…
Oct-30-23 08:00AM
Oct-25-23 08:01AM
Sep-26-23 08:01AM
Sep-05-23 08:00AM
Aug-21-23 08:00AM
Aug-10-23 08:01AM
Aug-09-23 10:26AM
Aug-07-23 02:34PM
Jul-14-23 04:40PM
Jul-10-23 08:26AM
Jul-07-23 08:38AM
06:52AM
Jun-12-23 08:01AM
Jun-09-23 04:01PM
Jun-01-23 09:55AM
08:00AM Loading…
08:00AM
May-27-23 09:07AM
May-26-23 09:55AM
May-25-23 09:55AM
May-23-23 07:41PM
04:01PM
04:00PM
May-10-23 08:00AM
May-09-23 08:00AM
Apr-12-23 08:00AM
07:07AM
Apr-10-23 06:44AM
Apr-05-23 08:35AM
Apr-04-23 08:00AM
Mar-27-23 09:55AM
Mar-07-23 12:00PM
Feb-28-23 08:00AM
Feb-10-23 08:53AM
07:59AM
Feb-09-23 04:01PM
Jan-28-23 01:58PM
Jan-24-23 09:02AM
Jan-13-23 06:56AM
Jan-08-23 06:00PM
Jan-06-23 05:02AM
Jan-05-23 11:31AM
Jan-04-23 09:17AM
Jan-03-23 04:01PM
Nov-08-22 05:00PM
Nov-03-22 08:30AM
Nov-01-22 08:00AM
Oct-24-22 08:00AM
Oct-23-22 12:01PM
Oct-18-22 08:00AM
Sep-26-22 08:00AM
Sep-07-22 08:15AM
Aug-17-22 09:16AM
Aug-02-22 08:00AM
Jun-01-22 08:15AM
May-25-22 08:00AM
May-24-22 12:15PM
May-17-22 08:01AM
May-11-22 10:54AM
May-10-22 08:00AM
May-04-22 08:01AM
May-03-22 05:40PM
Apr-26-22 08:00AM
Apr-13-22 02:10PM
Apr-01-22 08:01AM
Mar-22-22 08:02AM
Mar-14-22 08:02AM
Mar-01-22 04:04PM
Feb-11-22 08:52PM
Feb-09-22 04:04PM
Nov-23-21 04:00PM
Nov-12-21 04:30PM
Nov-10-21 08:32PM
Nov-08-21 08:00AM
Oct-27-21 09:47PM
Oct-26-21 04:01PM
Oct-24-21 03:30PM
Oct-21-21 08:00AM
Oct-18-21 12:14PM
10:28AM
08:20AM
07:00AM
Oct-11-21 03:55PM
Sep-27-21 03:50PM
08:00AM
Sep-20-21 08:00AM
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curran TerriePresident and Chief ExecutiveMar 22 '24Sale9.1116,851153,513410,784Mar 26 04:05 PM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerJan 24 '24Sale8.103,703,70329,999,9943,755,583Jan 25 06:13 AM
Henderson MollyCFO and CBOJan 19 '24Sale7.756,30748,90098,698Jan 22 08:22 PM
Henderson MollyCFO and CBONov 20 '23Sale7.242,12715,403103,061Nov 21 04:40 PM
Parikh AsitDirectorNov 08 '23Buy7.802,50019,50055,000Nov 08 07:56 PM
Parikh AsitDirectorNov 07 '23Buy7.764,00031,04052,500Nov 08 07:56 PM
Parikh AsitDirectorNov 06 '23Buy8.041,0008,04048,500Nov 08 07:56 PM
Henderson MollyCFO and CBONov 01 '23Sale8.8812,492110,871105,188Nov 03 04:55 PM
Henderson MollyCFO and CBOJun 02 '23Sale11.411,96022,36868,506Jun 05 06:32 PM
Henderson MollyCFO and CBOMay 22 '23Sale12.872,11027,16570,466May 23 12:15 PM
Nabulsi AzmiChief Operating OfficerApr 11 '23Buy8.2610,00082,60099,567Apr 11 04:05 PM
Parikh AsitDirectorApr 10 '23Buy7.551,0007,55023,500Apr 11 04:05 PM
Curran TerriePresident and Chief ExecutiveApr 06 '23Buy7.8212,919101,025188,290Apr 07 03:19 PM
Henderson MollyCFO and CBOApr 06 '23Sale7.273,43925,00272,576Apr 07 03:18 PM
Last Close
Mar 28 04:00PM ET
25.12
Dollar change
0.00
Percentage change
0.00
%
MIRM Mirum Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-4.03 Insider Own21.46% Shs Outstand46.72M Perf Week-3.53%
Market Cap1.17B Forward P/E40.31 EPS next Y0.62 Insider Trans-0.31% Shs Float36.61M Perf Month-13.05%
Income-160.91M PEG- EPS next Q-0.36 Inst Own91.35% Short Float22.23% Perf Quarter-16.43%
Sales186.37M P/S6.28 EPS this Y75.39% Inst Trans11.41% Short Ratio13.58 Perf Half Y-18.44%
Book/sh5.32 P/B4.72 EPS next Y164.27% ROA-32.20% Short Interest8.14M Perf Year9.74%
Cash/sh6.14 P/C4.09 EPS next 5Y- ROE-82.37% 52W Range21.83 - 35.56 Perf YTD-14.91%
Dividend Est.- P/FCF- EPS past 5Y-39.57% ROI-28.95% 52W High-29.36% Beta1.14
Dividend TTM- Quick Ratio4.19 Sales past 5Y88.90% Gross Margin75.98% 52W Low15.04% ATR (14)1.20
Dividend Ex-Date- Current Ratio4.45 EPS Y/Y TTM-0.28% Oper. Margin-57.22% RSI (14)36.30 Volatility3.75% 4.75%
Employees264 Debt/Eq1.24 Sales Y/Y TTM141.85% Profit Margin-86.33% Recom1.11 Target Price50.78
Option/ShortYes / Yes LT Debt/Eq1.23 EPS Q/Q28.44% Payout- Rel Volume0.71 Prev Close25.12
Sales Surprise2.49% EPS Surprise-162.39% Sales Q/Q149.24% EarningsFeb 28 AMC Avg Volume599.15K Price25.12
SMA20-7.80% SMA50-8.35% SMA200-11.34% Trades Volume424,360 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-18-23Reiterated H.C. Wainwright Buy $60 → $58
Nov-20-23Resumed JP Morgan Overweight $37
Nov-13-23Initiated Morgan Stanley Overweight $60
Oct-24-23Initiated Cantor Fitzgerald Overweight $50
Oct-17-23Resumed Evercore ISI Outperform $62
Sep-20-23Initiated JMP Securities Mkt Outperform $70
Sep-01-22Initiated Citigroup Buy $38
Sep-20-21Initiated JP Morgan Overweight $30
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Mar-25-24 11:46PM
07:00AM
Mar-15-24 09:32AM
Mar-13-24 06:00PM
Mar-08-24 07:30PM
08:00AM Loading…
Mar-05-24 08:00AM
Feb-29-24 11:34AM
09:49AM
08:30AM
Feb-28-24 05:35PM
04:38PM
04:03PM
Feb-21-24 04:05PM
Feb-09-24 09:15PM
Feb-05-24 07:00AM
11:44AM Loading…
Jan-23-24 11:44AM
Jan-19-24 09:30PM
Jan-16-24 08:30AM
Jan-15-24 04:03AM
Jan-10-24 07:00PM
Jan-08-24 08:30AM
Jan-03-24 08:45AM
Dec-18-23 01:05PM
08:37AM
08:30AM
Dec-08-23 07:30PM
Nov-30-23 09:45AM
Nov-20-23 04:05PM
Nov-13-23 02:00PM
Nov-10-23 05:30PM
09:10AM Loading…
Nov-06-23 09:10AM
Nov-03-23 08:30AM
Nov-02-23 07:13PM
04:05PM
Oct-30-23 10:00AM
08:30AM
Oct-27-23 08:45AM
Oct-17-23 04:30PM
Oct-11-23 04:52PM
Oct-10-23 08:00PM
Oct-07-23 05:00PM
Oct-02-23 08:30AM
Sep-26-23 08:30AM
Sep-21-23 08:30AM
Sep-15-23 03:05PM
08:30AM
06:01AM
Sep-14-23 01:15PM
Sep-13-23 01:01PM
Sep-11-23 10:07AM
Sep-08-23 11:30PM
Sep-06-23 11:19AM
08:30AM
Sep-05-23 08:30AM
08:30AM
Aug-10-23 07:00PM
Aug-03-23 05:25PM
04:05PM
Jul-27-23 04:05PM
Jul-25-23 05:12PM
08:30AM
Jul-20-23 08:18AM
Jul-18-23 10:48AM
Jul-17-23 02:18PM
08:00AM
08:00AM
Jul-10-23 08:00PM
Jun-29-23 09:27AM
Jun-23-23 12:00PM
Jun-14-23 08:30AM
Jun-09-23 09:30PM
Jun-07-23 08:30AM
Jun-02-23 08:49AM
May-19-23 07:00AM
May-18-23 08:30AM
May-17-23 08:30AM
May-11-23 08:30AM
May-10-23 09:00PM
May-09-23 02:59PM
May-06-23 08:05AM
May-04-23 06:05PM
04:02PM
May-01-23 10:00AM
Apr-27-23 04:02PM
10:02AM
Apr-25-23 05:44AM
Apr-18-23 06:15AM
Apr-13-23 12:15AM
Apr-12-23 07:00AM
06:59AM
Apr-10-23 08:30PM
Apr-06-23 08:30AM
Apr-05-23 08:30AM
Apr-02-23 11:36AM
Mar-31-23 06:39AM
Mar-15-23 09:05AM
Mar-14-23 08:30AM
Mar-11-23 06:40AM
Mar-10-23 08:30PM
Mar-09-23 12:27PM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BJERKHOLT ERICCHIEF FINANCIAL OFFICERMar 27 '24Buy24.802,00049,60014,000Mar 27 08:47 PM
Radovich PeterPRESIDENT AND COOMar 25 '24Sale25.804,303111,01729,013Mar 25 05:41 PM
BJERKHOLT ERICCHIEF FINANCIAL OFFICERMar 18 '24Buy25.802,00051,60012,000Mar 18 05:34 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERFeb 02 '24Sale26.196,013157,491104,112Feb 05 09:04 PM
Radovich PeterPRESIDENT AND COOFeb 02 '24Sale26.191,79046,88334,695Feb 05 09:05 PM
Vig PamelaCHIEF SCIENTIFIC OFFICERFeb 02 '24Sale26.191,21431,79728,691Feb 05 09:12 PM
Longpre LaraCHIEF DEVELOPMENT OFFICERFeb 02 '24Sale26.1984722,184104,407Feb 05 09:10 PM
Howe JolandaSVP, GLOBAL CONTROLLERFeb 02 '24Sale26.1973519,2511,759Feb 02 09:28 PM
Peetz ChristopherPRESIDENT AND CEOJan 08 '24Sale28.035,209146,033110,125Jan 09 08:12 PM
Radovich PeterCHIEF OPERATING OFFICERJan 08 '24Sale28.031,40839,47336,485Jan 09 08:28 PM
Vig PamelaHEAD OF RESEARCH & DEVELOPMENTJan 08 '24Sale28.031,40839,47229,905Jan 09 08:21 PM
Longpre LaraCHIEF DEVELOPMENT OFFICERJan 08 '24Sale28.041,01928,568105,254Jan 09 08:25 PM
Howe JolandaSVP, GLOBAL CONTROLLERJan 08 '24Sale28.0452814,803722Jan 09 08:09 PM
Howe JolandaSVP, Global ControllerDec 05 '23Option Exercise2.942,5007,3502,500Dec 06 05:16 PM
Howe JolandaSVP, Global ControllerDec 05 '23Sale32.402,50081,0000Dec 06 05:16 PM
GREY MICHAEL GDirectorSep 14 '23Option Exercise2.9414,21641,73814,216Sep 14 07:33 PM
GREY MICHAEL GDirectorSep 14 '23Sale32.0014,216454,9120Sep 14 07:33 PM
GREY MICHAEL GDirectorSep 13 '23Option Exercise2.943921,151392Sep 14 07:33 PM
Heron Patrick JDirectorSep 13 '23Buy31.022,62581,425159,053Sep 15 04:56 PM
GREY MICHAEL GDirectorSep 13 '23Sale32.0039212,5440Sep 14 07:33 PM
Heron Patrick JDirectorSep 12 '23Buy30.603,750114,764156,428Sep 13 04:39 PM
BJERKHOLT ERICChief Financial OfficerSep 11 '23Buy29.6510,000296,49210,000Sep 12 06:23 PM
Heron Patrick JDirectorSep 11 '23Buy30.304,687142,027152,678Sep 13 04:39 PM
Heron Patrick JDirectorAug 31 '23Buy26.25147,9913,884,764147,991Sep 05 12:51 PM
Howe JolandaSVP, Global ControllerAug 25 '23Sale26.233,45990,7430Aug 28 04:30 PM
Peetz ChristopherPresident and CEOJul 03 '23Sale25.655,498141,005115,334Jul 05 07:30 PM
Radovich PeterChief Operating OfficerJul 03 '23Sale25.651,42536,54637,675Jul 05 07:47 PM
Vig PamelaHead of Research & DevelopmentJul 03 '23Sale25.651,42536,54630,786Jul 05 07:35 PM
Longpre LaraChief Development OfficerJul 03 '23Sale25.651,00425,749105,839Jul 05 07:37 PM
Howe JolandaSVP, Global ControllerJul 03 '23Sale25.6591523,4673,459Jul 05 07:33 PM
GREY MICHAEL GDirectorJun 08 '23Option Exercise2.9414,60842,88914,608Jun 09 04:20 PM
GREY MICHAEL GDirectorJun 08 '23Sale29.0014,608423,6320Jun 09 04:20 PM
GREY MICHAEL GDirectorMay 03 '23Option Exercise2.9414,60842,88914,608May 04 09:58 PM
GREY MICHAEL GDirectorMay 03 '23Sale28.0014,608409,0240May 04 09:58 PM